Preclinical immunogenicity and protective efficacy of an oral Helicobacter pylori inactivated whole cell vaccine and multiple mutant cholera toxin: A novel and non-toxic mucosal adjuvant
- 1 October 2018
- Vol. 36 (41) , 6223-6230
Abstract
No abstract availableKeywords
Funding Information
- Sahlgrenska Academy
- Swedish Cancer Foundation
- STINT
- Swedish Research Council (348-2014-3071)
- Marianne and Marcus Wallenberg Foundation
- Swedish Strategic Research Foundatiońs Infection Biology Program
This publication has 28 references indexed in Scilit:
- A Double Mutant Heat-Labile Toxin from Escherichia coli, LT(R192G/L211A), Is an Effective Mucosal Adjuvant for Vaccination against Helicobacter pylori InfectionInfection and Immunity, 2013
- The Adjuvant Double Mutant Escherichia coli Heat Labile Toxin Enhances IL-17A Production in Human T Cells Specific for Bacterial Vaccine AntigensPLOS ONE, 2012
- The A Subunit of Escherichia coli Heat-Labile Enterotoxin Functions as a Mucosal Adjuvant and Promotes IgG2a, IgA, and Th17 Responses to Vaccine AntigensInfection and Immunity, 2012
- Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral AdjuvantClinical and Vaccine Immunology, 2011
- Proinflammatory Cytokine Gene Expression in the Stomach Correlates with Vaccine-Induced Protection against Helicobacter pylori Infection in Mice: an Important Role for Interleukin-17 during the Effector PhaseInfection and Immunity, 2011
- A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pyloriVaccine, 2011
- Sublingual Immunization Protects against Helicobacter pylori Infection and Induces T and B Cell Responses in the StomachInfection and Immunity, 2010
- Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxinVaccine, 2010
- Presence of High Numbers of Transcriptionally Active Helicobacter pylori in Vomitus from Bangladeshi Patients Suffering from Acute GastroenteritisHelicobacter, 2009
- “PERFEXT”: a direct method for quantitative assessment of cytokine production in vivo at the local levelResearch in Immunology, 1997